A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma

被引:0
|
作者
Wang, Xiaoxue [1 ]
Yan, Xiaojing [1 ]
Li, Yan [1 ]
机构
[1] China Med Univ, Hosp 1, Dept Hematol, Shenyang 110001, Peoples R China
关键词
Multiple myeloma; bisphosphonates; clodronate; pamidronate; zoledronic acid; meta-analysis; ZOLEDRONIC ACID THERAPY; LONG-TERM; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; PROSTATE-CANCER; ORAL CLODRONATE; DISEASE-FREE; FOLLOW-UP; SURVIVAL; SKELETAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The objective of this meta-analysis was to determine the effectiveness and safety of bisphosphonates (BPs) for patients with multiple myeloma (MM). Methods: The study included patients with MM, who were randomly allocated to receive either BPs or control. PubMed/Medline, Embase, the Cochrane Database of Systematic Reviews (CDSR), and the Cochrane Central Register of Controlled Trials were searched up to January 2014, and only published trials were included in the analysis. There was no language restriction. The results were analyzed using RevMan 5.2 software, which was provided by Cochrane Collaboration. Results: Six randomized controlled trials (RCTs) covering 1951 patients with MM were included in the analysis. The clodronate subgroup showed superior progression-free survival compared to the other groups. The pooled hazard ratio (HR) was 0.57 [95% confidence interval (CI) 0.33-0.99, P = 0.04]. Regarding overall survival (OS), only zoledronic acid showed a clear advantage (HR = 0.51, 95% CI 0.33-0.77, P = 0.002) All BPs were effective at reducing skeletal-related events (SREs). The pooled risk ratios for the outcome of SREs were 0.72 (95% CI: 0.62-0.84, P < 0.0001) for the clodronate subgroup, 0.66 (95% CI: 0.48-0.91, P = 0.007) for the pamidronate subgroup, and 0.65 (95% CI: 0.46-0.91, P = 0.01) for the zoledronic acid subgroup. Several adverse events (AEs) were mentioned in the included RCTs; however, the pooled results showed no statistically significant differences between the BP groups and the control. Conclusions: The present meta-analysis demonstrated that zoledronic acid may improve the OS of patients with MM. All BPs markedly decreased SREs and were tolerated well.
引用
收藏
页码:6743 / 6754
页数:12
相关论文
共 50 条
  • [1] Bisphosphonates in multiple myeloma: a network meta-analysis
    Mhaskar, Rahul
    Redzepovic, Jasmina
    Wheatley, Keith
    Camara Clark, Otavio Augusto
    Miladinovic, Branko
    Glasmacher, Axel
    Kumar, Ambuj
    Djulbegovic, Benjamin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (05):
  • [2] Bisphosphonates in multiple myeloma: an updated network meta-analysis
    Mhaskar, Rahul
    Kumar, Ambuj
    Miladinovic, Branko
    Djulbegovic, Benjamin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (12):
  • [3] Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma
    Wang, Pei
    Jin, Sheng-Yu
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (29) : 7091 - 7100
  • [4] Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis
    Wang, Yin
    Li, Yanqing
    Chai, Ye
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (08)
  • [5] The role of bisphosphonates in multiple myeloma: Meta-analysis of published randomized trials.
    Djulbegovic, B
    Wheatley, K
    Lacevic, M
    Bos, G
    Ross, J
    Goldschmidt, H
    Glasmacher, A
    BLOOD, 2000, 96 (11) : 286B - 286B
  • [6] Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma
    Knopf, Kevin B.
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Gravel, Jonathan
    Lefebvre, Patrick
    Niculescu, Liviu
    Ba-Mancini, Abbie
    Ma, Esprit
    Shi, Hongliang
    Comenzo, Raymond L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 380 - 388
  • [7] Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis
    Palmieri, Carlo
    Fullarton, John R.
    Brown, Janet
    CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6863 - 6872
  • [8] Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis
    Mhaskar, Rahul Suresh
    Redzepovic, Jasmina
    Wheatley, Keith
    Clark, Otavio
    Glasmacher, Axel
    Kumar, Ambuj
    Djulbegovic, Benjamin
    BLOOD, 2009, 114 (22) : 1484 - 1484
  • [9] A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives
    Chatziravdeli, Vasiliki
    Katsaras, Georgios N.
    Katsaras, Dimitrios
    Doxani, Chrysoula
    Stefanidis, Ioannis
    Zintzaras, Elias
    JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 2022, 22 (04) : 596 - 621
  • [10] Neuropathy as an adverse effect of proteasomal inhibitors in multiple myeloma treatment: a network meta-analysis
    Garg, Anisha
    Das, Avash
    Dasgupta, Subhajit
    Kumar, Shaji
    Roy, Bhaskar
    NEUROLOGY, 2023, 100 (17)